Posted by Michael Wonder on 08 Feb 2023
Bayer submits aflibercept 8 mg for regulatory approval in two major retinal eye diseases in the EU
6 February 2023 - Filing for aflibercept 8 mg in neovascular (wet) age-related macular degeneration and diabetic macular oedema is based on positive results of clinical trials, PULSAR and PHOTON.
Bayer has submitted an application for market authorisation to the EMA for aflibercept 8 mg in two major retinal eye diseases, neovascular (wet) age-related macular degeneration and diabetic macular oedema.
